ReviewCureus2025
Emerging Novel Biomarkers in Allergic Rhinitis: A Narrative Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Identification of EGR2 and TGFB1 as Potential Immunoregulatory Biomarkers for Allergic Rhinitis: An Exploratory Bioinformatics and Pilot Validation Study.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
- TRPM2 Deficiency Attenuates Allergic Rhinitis-Like Inflammation With Altered CaImmunity, inflammation and disease · 2026Article
- Th17/Treg cell imbalance in allergic rhinitis: mechanisms and therapeutic implications.Genes and immunity · 2026Review
- Local immune and inflammatory endotypes of the nasal mucosa in allergic and non-allergic chronic rhinitis.Frontiers in immunology · 2026Article
- Efficacy of Lactobacillus and Bifidobacterium in Allergic Rhinitis: A Narrative Review.Cureus · 2025Review
- Progress in research on predictors of adverse outcomes in patients with nasal inflammatory diseases.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergic rhinitis (AR) is a highly prevalent, immunoglobulin E (IgE)-mediated inflammatory condition that significantly impacts global public health. While conventional biomarkers such as total and specific IgE and eosinophil counts are widely used, their limitations in diagnostic precision and treatment response prediction have prompted research into novel biomarkers. This review synthesizes emerging evidence from the past 15 years on innovative molecular markers implicated in AR pathogenesis and management. A comprehensive literature search identified preclinical and clinical studies investigating promising biomarkers, including periostin, microRNA-155, hypoxia-inducible factor 1-alpha (HIF-1α), Granzyme A (GZMA), CD39, and several serum and nasal fluid proteins such as orosomucoid (ORM), apolipoprotein H (APOH), and serpin family b member 3 (SERPINB3). Preclinical models highlighted their roles in immune regulation, barrier dysfunction, and inflammatory cascades. Clinical trials confirmed their diagnostic, prognostic, and therapeutic monitoring potential. Notably, periostin and miRNA-155 were associated with disease severity and responsiveness to sublingual immunotherapy, while proteins such as ORM and APOH predicted glucocorticoid (GC) treatment outcomes. CD39 and cytokine profiles showed promise for stratifying disease severity. Despite these advances, most biomarkers remain in investigational stages. Future work should emphasize multicenter validation and standardized protocols, and integration into biomarker panels for personalized AR care. This review underscores the evolving landscape of AR biomarker research and its translational potential in precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.